Sometimes immunohistochemistry is helpful not only to identify the particular kind of lymphoma but also to help shape a prognosis, based on markers that are associated with a more slow-growing behavior vs. a more aggressive type. IHC for Lymphomas Lymphomas are considered malignancies of lymphocytes ...
Reference: The Use of Immunohistochemistry for Diagnosis of Prostate Cancer, Katia R. M. Leite, et al. Cancer markers ALK gene rearrangements Cancer types: Non-small cell lung cancer and anaplastic large cell lymphoma Tissue analyzed: Tumor ...
Introduction: MYC+BCL2+ double expression (DE) is a biomarker for poor prognosis in diffuse large B-cell lymphoma (DLBCL), likely due to the cooperation between MYC and BCL2 oncoproteins in tumor cells. However, as generally MYC and BCL2 are separately assessed on two different slides by ...
Abstract B008: High expression of the exhaustion markers PD1 and PD-L1 in non-muscle invasive bladder cancer is associated with poor outcome following Baci... Introduction: The recommended treatment for high-risk non-muscle invasive bladder cancer (NMIBC) is intravesical instillations of Bacillus Cal...
Accurate, cost-effective methods for testing anaplastic lymphoma kinase gene rearrangement (ALK+) are needed to select patients with non-small cell lung carcinoma for ALK-inhibitor therapy. Fluorescent in situ hybridization (FISH) is used to detect ALK+, but it is expensive and not routinely avail...